T. Bachelot (Lyon, France)
Centre Léon BérardAuthor Of 1 Presentation
Do CNS metastases in HER2+ breast cancer require a different systemic approach? (ID 230)
Presenter Of 1 Presentation
Do CNS metastases in HER2+ breast cancer require a different systemic approach? (ID 230)
Author Of 1 Presentation
110P - Adenoid cystic carcinoma of the breast: a case series of 17 patients and literature review
Abstract
Background
Adenoid cystic carcinoma (ACC) of the breast is a rare and indolent tumor associated to good prognosis despites its triple-negative status. Due to its paucity, there are no therapeutic consensus or treatment guidelines.
Methods
Here, we report on 17 patients with ACC of the breast from the database of the Leon Berard cancer center in Lyon. Clinical, histological and molecular features of these carcinomas were characterized. Therapeutic management of patients has been described. Follow-up was done for all patients.
Results
Median age was 59 years [22-77] and median follow-up was 3.2 years [0.5-23.9]. Median tumor size was 16mm [8-60]. Only one patient had axillary node metastases. Only 3 tumors were ER or PR positive. All tumors were HER-2 negative. Five patients had a rearrangement of the MYB gene. All patients had initial surgery followed by radiotherapy. Adjuvant chemotherapy was administered to one patient, and 2 patients received adjuvant endocrine therapy. At last follow-up, none of the patients had died from complications of the disease.
Conclusions
If ACC are tumors with good prognosis, the occurrence of local relapse or metastases may happen, which requires to maintain long-term follow up. A better understanding of molecular genetic features may help the development of specific therapeutic strategies.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.